Shandong Kexing Bioproducts Co,.Ltd (688136.SS)
CNY 21.18
(-1.72%)
CNY 21.18
(-1.72%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.4 Billion CNY | 3.51% |
| 2022 | 1.35 Billion CNY | 47.32% |
| 2021 | 918.34 Million CNY | 71.17% |
| 2020 | 536.49 Million CNY | 10.92% |
| 2019 | 483.66 Million CNY | 34.4% |
| 2018 | 359.86 Million CNY | -32.22% |
| 2017 | 530.96 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.37 Billion CNY | -7.16% |
| 2024 Q1 | 1.43 Billion CNY | 2.84% |
| 2024 Q2 | 1.48 Billion CNY | 3.21% |
| 2023 FY | 1.4 Billion CNY | 3.51% |
| 2023 Q2 | 1.45 Billion CNY | 10.41% |
| 2023 Q1 | 1.31 Billion CNY | -2.48% |
| 2023 Q4 | 1.4 Billion CNY | -0.66% |
| 2023 Q3 | 1.4 Billion CNY | -3.23% |
| 2022 Q2 | 1.16 Billion CNY | 16.44% |
| 2022 FY | 1.35 Billion CNY | 47.32% |
| 2022 Q4 | 1.35 Billion CNY | 7.45% |
| 2022 Q3 | 1.25 Billion CNY | 7.97% |
| 2022 Q1 | 1 Billion CNY | 9.05% |
| 2021 FY | 918.34 Million CNY | 71.17% |
| 2021 Q2 | 558.34 Million CNY | 22.89% |
| 2021 Q3 | 716.08 Million CNY | 28.25% |
| 2021 Q4 | 918.34 Million CNY | 28.24% |
| 2021 Q1 | 454.33 Million CNY | -15.31% |
| 2020 Q3 | 500.5 Million CNY | 6.59% |
| 2020 FY | 536.49 Million CNY | 10.92% |
| 2020 Q2 | 469.54 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q4 | 536.49 Million CNY | 7.19% |
| 2019 Q4 | 483.66 Million CNY | 0.0% |
| 2019 FY | 483.66 Million CNY | 34.4% |
| 2018 FY | 359.86 Million CNY | -32.22% |
| 2017 FY | 530.96 Million CNY | 0.0% |